PBM Reimbursement Survival Guide: How Independent Pharmacies Can Fight Back in 2026

The $0.88 Prescription That Could Close Your Pharmacy

A pharmacist in rural Mississippi recently shared a story that has become painfully common: she filled a branded prescription that cost her pharmacy $929.07 to acquire. The PBM reimbursed her $804.19. She lost nearly $125 on a single transaction — and she had no choice but to fill it.

That is not an isolated incident. According to the National Community Pharmacists Association, more than half of independent pharmacy owners are now losing money on over 60 percent of the Part D prescriptions they fill. Read that again. The majority of prescriptions flowing through independent pharmacies are underwater.

The NCPA's January 2025 member survey paints an even grimmer picture: 96.5 percent of independent pharmacists said PBM reimbursement for Medicare Part D threatens the viability of their business. Nearly half reported that their financial health declined significantly in 2024. And 30.3 percent said they are considering closing their doors in the coming year.

Independent pharmacies are closing at a rate of roughly one per day nationwide. In Mississippi alone, 312 independent pharmacies have closed since 2010, leaving entire communities with 20-mile drives to the nearest pharmacy. The PBM reimbursement crisis is not a future threat — it is happening right now.

How PBMs Are Squeezing Independent Pharmacies

Understanding the mechanics of the squeeze helps you fight it. PBMs use several tactics that systematically erode pharmacy margins:

Below-cost reimbursement. PBMs set reimbursement rates below what pharmacies pay to acquire medications. When you are reimbursed $0.95 for a pill that costs you $1.00 to buy, you lose money on every fill. Multiply that across hundreds of prescriptions per week and the losses compound fast.

Spread pricing. PBMs charge health plans one price for a drug and pay the pharmacy a lower price, pocketing the difference. Ohio's state auditor found that PBMs kept $224.8 million through spread pricing alone during a single year — money extracted from a $2.5 billion Medicaid drug spend.

Retroactive DIR fees. Direct and Indirect Remuneration fees are clawed back from pharmacies weeks or months after a prescription is filled. One Mississippi pharmacy reported DIR fees exceeding $100,000 in 2025. Extrapolated across all independent pharmacies in the state, that represents over $30 million per year taken from pharmacies after they have already dispensed the medication.

Patient steering. PBMs that own their own mail-order pharmacies actively direct patients away from independent pharmacies and toward their own vertically integrated operations. This creates a system where the entity setting your reimbursement rates is also your direct competitor.

The Legislative Landscape Is Shifting — But Slowly

There is reason for cautious optimism on the legislative front. Mississippi's House passed a PBM reform bill by a 76-38 vote in early 2026, requiring PBMs to reimburse pharmacists at least their cost of acquiring a drug. Oklahoma already has a law allowing pharmacies to decline dispensing when PBM reimbursement falls below acquisition cost. Iowa has banned below-acquisition reimbursement and prohibited spread pricing entirely.

At the federal level, the FTC's ongoing investigation into PBM practices and bipartisan congressional interest in reform suggest that change is coming. But legislative timelines are unpredictable, and independent pharmacies cannot afford to wait for lawmakers to save them. You need a survival strategy that works today.

Five Strategies to Survive and Grow Despite PBM Pressure

1. Diversify Revenue Beyond the Dispensing Counter

The fundamental problem is dependency on PBM-controlled prescription revenue. Every dollar you earn from a non-PBM source is a dollar no middleman can claw back.

High-margin revenue streams that PBMs cannot touch:

• Clinical services — immunizations, point-of-care testing, medication therapy management, chronic disease programs, and health screenings generate direct revenue billed through medical benefit rather than pharmacy benefit
• Compounding — custom formulations carry margins that mass-market pharmacies and PBM-owned mail-order operations cannot match
• Cash-pay programs — transparent cash pricing for generics often beats insurance copays, removes the PBM from the transaction entirely, and builds patient loyalty
• Front-end retail — vitamins, supplements, durable medical equipment, and specialty health products provide margin without PBM involvement

The pharmacies that survive the PBM squeeze will be the ones that treat dispensing as one revenue stream among many, not the only one.

2. Build a Direct-to-Patient Digital Channel

When patients interact with your pharmacy exclusively through a PBM's network, the PBM controls the relationship. Building a direct digital presence — online ordering, prescription refills, OTC product sales, secure messaging — creates a channel between you and your patients that no PBM intermediary can disrupt.

An online storefront for OTC products, supplements, and health supplies generates revenue completely outside the PBM ecosystem. Patients who can refill prescriptions, browse products, and communicate with your pharmacist through your own platform are significantly less likely to be steered toward a PBM-owned mail-order alternative.

This does not require a massive technology investment. Purpose-built pharmacy e-commerce platforms can get an independent pharmacy online in under 24 hours with HIPAA-compliant infrastructure, prescription management, and delivery tracking included.

3. Fight Back on Underwater Claims

Too many pharmacies passively accept below-cost reimbursements. You have more leverage than you think:

• Track every underwater claim. Maintain a detailed log of prescriptions where reimbursement falls below acquisition cost. This data is powerful when filing complaints with state boards of pharmacy, insurance commissioners, and legislative representatives.
• Use your state's appeal process. Most states require PBMs to offer a reimbursement appeal mechanism. Use it for every below-cost claim, even when the process feels futile. Volume of appeals creates a paper trail that regulators notice.
• Know your state's protections. Several states now have laws addressing below-cost reimbursement. If your state has passed PBM reform legislation, make sure you understand and exercise your rights under it.
• Join collective advocacy efforts. NCPA, state pharmacy associations, and pharmacist-led coalitions are actively lobbying for federal reform. Your participation, testimony, and data strengthen the case.

4. Strengthen Patient Loyalty Before PBMs Redirect Them

PBMs spend significant resources steering patients toward their own mail-order pharmacies. Your defense is a patient relationship so strong that patients actively resist being redirected.

• Proactive refill outreach — text and email reminders before patients run out
• Medication cost advocacy — actively find coupons, generics, and assistance programs that save patients money
• Same-day local delivery — a service Amazon and mail-order pharmacies cannot match on speed and personal touch
• Community health events — flu clinics, health screenings, and educational workshops build the kind of trust no mail-order operation can replicate

Patients who see their pharmacist as a healthcare partner — not just a pill dispenser — are far more resistant to PBM steering tactics.

5. Optimize Your PBM Contract Portfolio

Not all PBM contracts are equally bad. Regularly evaluate which contracts are profitable and which are costing you money:

• Audit your top 50 drugs by volume against each PBM's reimbursement rates
• Identify and drop the worst contracts if your patient volume can absorb the shift
• Negotiate preferred network status where possible — preferred pharmacies typically receive better reimbursement rates in exchange for meeting performance metrics
• Consider PSAO membership — Pharmacy Services Administrative Organizations negotiate PBM contracts on behalf of independent pharmacy groups, providing leverage that individual pharmacies lack

The Pharmacies That Will Still Be Here in 2030

The independent pharmacies that survive the current PBM reimbursement crisis will share a common trait: they refused to let their entire business model depend on a system designed to minimize what they earn. They diversified revenue, built direct patient relationships, went digital, fought underwater claims, and optimized their contracts.

The PBM landscape will eventually change — legislatively, regulatorily, or through market pressure. But the pharmacies that wait for rescue without adapting will not be around to benefit from it.

If building a digital revenue channel is on your list, pharmacy-specific e-commerce platforms make it possible to launch an online storefront without custom development or six-figure budgets. The important thing is to start building revenue streams that no PBM can touch — because the pharmacies that depend entirely on dispensing margins are the ones closing their doors.